Mazdutide
A dual glucagon / GLP-1 agonist; country-specific status matters.
Investigational / no FDA-approved-treatment claim
A dual glucagon / GLP-1 agonist; country-specific status matters.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proposed and studied uses include chronic weight management in people with obesity or overweight.
A 2025 trial reports results in Chinese adults. Innovent announced Chinese NMPA approval on June 27, 2025. That is country-specific sponsor-reported approval, not evidence of FDA approval.
Evidence and source limits
The original trial and sponsor announcement provide China-specific context, not an FDA approval. FDA status is not established by these sources. Approval in one jurisdiction must not be transferred to another country or an unrelated preparation.
Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.